BREXAFEMME Drug Patent Profile

When do Brexafemme patents expire, and when can generic versions of Brexafemme launch?

Brexafemme is a drug marketed by Glaxosmithkline and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in BREXAFEMME is ibrexafungerp citrate. Additional details are available on the ibrexafungerp citrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Brexafemme

Brexafemme was eligible for patent challenges on June 1, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 1, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for BREXAFEMME

US Patents:	5
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for BREXAFEMME

BREXAFEMME is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes			Y	Y
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes			Y	Y

International Patents for BREXAFEMME

When does loss-of-exclusivity occur for BREXAFEMME?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Lithuania

Poland

Portugal

San Marino

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BREXAFEMME around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1125272
Denmark	3247711
Eurasian Patent Organization	036874	НОВЫЕ СОЛИ И ПОЛИМОРФЫ SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078)
Eurasian Patent Organization	201791645	НОВЫЕ СОЛИ И ПОЛИМОРФЫ SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078)
European Patent Office	3247711	NOUVEAUX SELS ET POLYMORPHES DE SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078)
European Patent Office	4039684	NOUVEAUX SELS ET POLYMORPHES DE SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078)

Analysis of BREXAFEMME: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

Brexafemme (ibrexafungerp), developed by Scynexis Inc., is a novel antifungal treatment approved by the U.S. FDA in 2021 for recurrent vulvovaginal candidiasis (RVVC). Its unique mechanism of action and broad-spectrum antifungal capabilities position it as a potentially transformative asset within the antifungal market. This report evaluates the investment landscape, market dynamics, and projected financial trajectory for BREXAFEMME, providing strategic insights for stakeholders.

---

1. Market Overview and Therapeutic Landscape

1.1. Target Indication and Epidemiology

• Recurrent Vulvovaginal Candidiasis (RVVC): Affects approximately 138 million women annually worldwide, with approximately 8-10% experiencing recurrent episodes (≥4 episodes/year) [1].
• Market Size:
  • United States: Estimated at $1.2 billion in 2022, with significant growth potential due to under-treatment and new therapeutic options.
  • Global Market: Projected to reach $2.8 billion by 2027, driven by increasing incidence and awareness [2].

1.2. Existing Therapeutics and Competitive Landscape

Current Market Players	Mechanism	Limitations	Market Share (Est.)
Fluconazole	Azole antifungal (triazole class)	Resistance, recurrence, drug interactions	~70%
Itraconazole	Azole antifungal	Limited efficacy, safety concerns	~20%
Topical agents	Various (clotrimazole, miconazole)	Limited systemic efficacy	~10%
Brexafemme (IBX)	Novel glucan synthase inhibitor	Pending long-term, real-world efficacy data	N/A

Market Gap: Resistance to azoles, recurrence, limited dosing options, and patient dissatisfaction underline the need for new therapies like Brexafemme.

---

2. Product Profile and Clinical Data

Brexafemme (ibrexafungerp) key attributes:

• Mechanism: Glucan synthase inhibition, similar to echinocandins; offers oral administration.
• Approval: FDA (August 2021) for RVVC.
• Dosage: 300 mg twice daily for 1 day, followed by weekly dosing.
• Efficacy: 76% clinical cure in Phase 3 (VANESSA trial), superior to placebo [3].

Advantages over existing options:

• Oral bioavailability.
• Reduced resistance potential.
• Broad-spectrum activity, including resistant strains.

---

3. Investment Scenario

3.1. Revenue Projections

Year	Projected Global Sales	Assumptions	Comments
2023	$50 million	Launch ramp-up, initial uptake	Focus on U.S. market
2024	$150 million	Increased prescriber adoption, expanded formulary	US market penetration, emerging international markets
2025	$300 million	Market penetration, insurance coverage improves	Broader awareness and recurrent treatment cycles
2026+	$500+ million	Sustained growth, potential label expansion	Possible indications for other vulvovaginal infections

Note: These estimates derive from comparables (e.g., Flucanzole, Luliconazole) adjusted for Brexafemme's unique profile and unmet needs [4].

3.2. Cost and Margin Considerations

• Pricing: Estimated at $2,000–$2,500 per treatment course in the U.S.
• Gross Margins: 70%–80%, considering manufacturing and distribution.
• R&D & Commercialization Expenses: Approximate $150–$200 million annually post-launch.

3.3. Market Penetration Strategies

• Key Channels: Obstetricians, gynecologists, primary care.
• Reimbursement: Secured via insurance coverage, potentially favorable due to clinical benefits.
• International Expansion: Focus on Europe (EMA approval), Japan, and emerging markets.

---

4. Market Dynamics and Competitive Factors

4.1. Regulatory and Policy Influences

• FDA and EMA approvals are critical milestones.
• Orphan Drug Designations (if applicable) could provide benefits.
• Reimbursement policies heavily influence uptake.

4.2. Key Competitive Dynamics

Factor	Impact on Market Trajectory
Resistance trends	Favorable positioning for new agents like Brexafemme
Patent life and exclusivity	Opportunity for extended market dominance
Pricing pressures	Balancing profitability and market share
Emerging generic antifungals	Might erode margins but less relevant initially
Academic and clinical adoption	Essential for sustained growth

4.3. International Market Entry Risks

• Regulatory delays.
• Local generic competitors.
• Differing healthcare reimbursement landscapes.

---

5. Financial Trajectory and Investment Outlook

Metrics	2023	2024	2025	2026+
Revenue	$50M	$150M	$300M	$500M+
Operating Margin	15-20%	20-25%	25-30%	30-40%
EBITDA	$10–$20M	$30–$75M	$75–$125M	$150M+
Market Share (Est.)	10-15%	20-30%	30-40%	50%+

Projection based on market uptake, competitive landscape, and payer dynamics.

---

6. Comparative Analysis: Key Differentiators vs. Competitors

Parameter	Brexafemme	Fluconazole	Other Topical Agents
Oral Administration	Yes	Yes	No
Resistance Profile	Minimal resistance	Rising resistance	Limited systemic efficacy
Spectrum of Activity	Broad-spectrum (candida, others)	Narrow (candida spp.)	Topical only
Market Penetration Potential	High due to convenience	Saturated, but resistance risk	Limited to symptomatic use

---

7. Regulatory & Patent Considerations

• Patent Life: Expected to provide market exclusivity until ~2030–2035, depending on jurisdiction.
• Patent Risks: Potential challenges from generic manufacturers post-expiry.
• Regulatory Milestones: Additional indications (e.g., Candida esophagitis), label expansions, and post-marketing studies could sustain growth.

---

8. Strategic Recommendations for Investors

• Monitor clinical trials: Future studies on broader indications could unlock additional revenue streams.
• Track regulatory updates: Approval in key international markets enhances market trajectory.
• Assess pricing strategies: Potential for premium pricing based on efficacy and convenience.
• Evaluate competitive threats: Emerging antifungal agents, especially with novel mechanisms.
• Consider partnership opportunities: Licensing, co-marketing, or acquisitions to accelerate growth.

---

Key Takeaways

• BREXAFEMME addresses a significant unmet need in RVVC with a promising clinical profile.
• The drug has moderate to high growth potential, contingent on successful market penetration and international expansion.
• The primary revenue driver hinges on its unique oral administration and reduced resistance concerns.
• Market dynamics favor early adoption in the US, with international opportunities present but subject to regulatory timelines.
• Investors should monitor clinical and regulatory developments, as well as evolving resistance trends impacting the antifungal market.

---

FAQs

Q1: How does BREXAFEMME compare to established antifungals like fluconazole?
A1: BREXAFEMME offers oral administration similar to fluconazole but has demonstrated efficacy against fluconazole-resistant strains, positioning it as a superior option for recurrent infections, particularly where resistance limits fluconazole's effectiveness.

Q2: What are the major risks to BREXAFEMME’s financial trajectory?
A2: Key risks include delayed regulatory approvals internationally, emergence of competing therapies, reimbursement challenges, and potential resistance development that could reduce its effectiveness over time.

Q3: When is BREXAFEMME expected to face patent expiry?
A3: Patent exclusivity is expected to last until approximately 2030–2035, with supplementary patents potentially extending exclusivity.

Q4: What is the potential for BREXAFEMME to expand into other indications?
A4: Clinical development pathways for other vulvovaginal candidiasis forms or systemic fungal infections are plausible but depend on successful trial outcomes and regulatory clearances.

Q5: How does market penetration differ across geographic regions?
A5: The U.S. is the initial focus due to regulatory approval; Europe and Asia require separate approvals. Market penetration depends on local reimbursement policies, healthcare infrastructure, and clinician awareness.

---

References

[1] Sobel JD. Vulvovaginal candidiasis. Lancet. 2007;369(9577):1961-1971.
[2] MarketsandMarkets. Antifungal drugs market by type, application, and region — Global forecast to 2027. April 2022.
[3] Raad I, et al. Efficacy and safety of ibrexafungerp in recurrent vulvovaginal candidiasis: phase 3 VANESSA study. J Infect Dis. 2021.
[4] EvaluatePharma. 2022 Forecast Reports.